Literature DB >> 28706396

An atypical presentation of alveolar soft part sarcoma of tongue.

Neha Chopra1, Nadeem Tanveer1.   

Abstract

Entities:  

Year:  2017        PMID: 28706396      PMCID: PMC5496304          DOI: 10.4103/JLP.JLP_22_17

Source DB:  PubMed          Journal:  J Lab Physicians        ISSN: 0974-2727


× No keyword cloud information.
Sir, Alveolar soft part sarcoma (ASPS) is a rare and aggressive tumor in adolescents and young adults with uncertain histogenesis. It comprises <1% of all soft tissue sarcomas with a female predominance. ASPS commonly involves the upper and lower extremities and is uncommonly seen in the head and neck region.[1] It usually affects young adults and adolescents between 15 and 35 years of age. Tumors occurring in infancy and childhood have a predilection for head and neck region, especially orbit and tongue.[2] There is slight female preponderance before the age of 30 and slight male preponderance over 30 years of age. A 35-year-old male presented with mass in the right lateral border of tongue [Figure 1], associated with slowly progressive dysphagia for solids and a single episode of oral bleeding. The lesion developed as a 0.5 cm nodule and progressed to its present size involving right lateral half of the tongue over a period of 3 months. His oropharyngeal examination revealed soft fleshy mass of 2 cm × 2 cm involving right lateral border of tongue. Difficulty in tongue movement was also noted. Contrast-enhanced computed tomography showed an irregularly enhancing lesion in the right lateral aspect of tongue measuring 3.3 cm × 2.1 cm reaching up to medial aspect of left hemitongue and inferiorly up to sublingual space on the right side. Enlarged lymph nodes were also noted in bilateral submandibular and upper deep cervical regions.
Figure 1

(a) Soft fleshy mass involving right hemitongue. (b) Cells arranged in pseudoalveolar pattern (H and E, ×100). (c and d) Cells with abundant granular eosinophilic cytoplasm, large nuclei with open chromatin and prominent nucleoli (H and E, ×200 and ×400)

(a) Soft fleshy mass involving right hemitongue. (b) Cells arranged in pseudoalveolar pattern (H and E, ×100). (c and d) Cells with abundant granular eosinophilic cytoplasm, large nuclei with open chromatin and prominent nucleoli (H and E, ×200 and ×400) An incisional biopsy was performed [Figure 1] which revealed tumor in subepithelium composed of epithelioid cells arranged in alveolar and solid pattern with intervening thin-walled blood vessels. The cells had a moderate amount of cytoplasm, round nuclei, and prominent eosinophilic nucleoli and showed increased mitotic activity. Immunohistochemical studies and special stains were performed to confirm the diagnosis. The tumor was positive for neuron-specific enolase (NSE) and vimentin and negative for desmin, HMB-45, and cytokeratin (CK). Periodic acidSchiff-reaction with diastase digestion highlighted intracytoplasmic needle-shaped crystals consistent with the diagnosis of ASPS [Figure 2]. Computerized tomographic examination of the chest and abdomen was performed, and metastasis to lung and liver ruled out. The patient was referred to an oncology center for oncosurgery and further management.
Figure 2

Immunohistochemical findings. (a) Diffuse cytoplasmic staining with neuron-specific enolase. (b) Cytoplasmic staining with vimentin. (c) Negative staining with cytokeratin. (d) Periodic acid–Schiff-positive, diastase-resistant crystals (PAS, ×200)

Immunohistochemical findings. (a) Diffuse cytoplasmic staining with neuron-specific enolase. (b) Cytoplasmic staining with vimentin. (c) Negative staining with cytokeratin. (d) Periodic acidSchiff-positive, diastase-resistant crystals (PAS, ×200) The first case of ASPS was described in 1952.[2] ASPS of tongue is usually a slow-growing tumor; however, in our case, patient presented with a rapidly growing lesion over a period of 3 months, which has not been described previously. The clinicopathologic characters of oral ASPS differ from that of extremities. Oral ASPS shows higher female predominance than extremity ASPS. Lingual ASPS is usually smaller in size. Smaller size and early diagnosis account for better prognosis of oral ASPS.[3] ASPS is classified under tumors of uncertain differentiation in 2002 WHO classification of soft tissue tumors. Earlier ASPS was considered to be of neural origin, but recent immunohistochemical studies have proved it to be of uncertain differentiation.[4] Twenty-five percent cases demonstrate NSE or S-100 positivity.[5] CK, epithelial membrane antigen, and neurofilament have been consistently negative. ASPS is usually slow growing and deceptively appears histologically benign with no atypical mitosis or nuclear pleomorphism. However, in our case, the mitotic activity was considerably high with the presence of atypical mitosis. The tumor spread is primarily hematogenous with lymphatic involvement being extremely rare being reported in 7% cases of head and neck ASPS.[1] The differential diagnostic possibilities include granular cell tumor, perivascular epithelioid cell tumors, clear cell sarcoma, extrarenal rhabdoid tumor, paraganglioma, and alveolar rhabdomyosarcoma.[2] The pathognomonic histologic feature of ASPS[2] is the presence of granules and rhomboid/rod-shaped crystalline intracytoplasmic inclusions reported in 25%–100% cases.[2] Periodic acidSchiff-positive, diastase-resistant granules may represent precursors to rod-shaped crystals. Complete surgical excision is the mainstay of treatment. Role of adjuvant therapy remains controversial, but radiotherapy/chemotherapy may be given in cases of inadequate surgical excision.[26] The prognostic parameters of ASPS include age at diagnosis, tumor size, and presence of metastasis. The clinical features and microscopic appearance of ASPS are variable and may develop unusual features as in our case. Lingual ASPS has a good prognosis and long tumor-free survival if diagnosed and treated early. A thorough histologic and radiologic examination becomes the basis of reliable diagnosis.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.
  6 in total

1.  Alveolar soft-part sarcoma of the head and neck: clinical and imaging features in five cases.

Authors:  Ho Sung Kim; Ho Kyu Lee; Young-Cheol Weon; Hyung-Jin Kim
Journal:  AJNR Am J Neuroradiol       Date:  2005 Jun-Jul       Impact factor: 3.825

Review 2.  Oral alveolar soft part sarcoma in childhood and adolescence: report of two cases and review of literature.

Authors:  Prokopios P Argyris; Robyn C Reed; J Carlos Manivel; Dolores Lopez-Terrada; Jared Jakacky; Zuzan Cayci; Konstantinos I Tosios; Stefan E Pambuccian; Lester D R Thompson; Ioannis G Koutlas
Journal:  Head Neck Pathol       Date:  2012-09-08

3.  Angiogenesis-promoting gene patterns in alveolar soft part sarcoma.

Authors:  Alexander J F Lazar; Parimal Das; Daniel Tuvin; Borys Korchin; Quansheng Zhu; Zeming Jin; Carla L Warneke; Peter S Zhang; Vivian Hernandez; Dolores Lopez-Terrada; Peter W Pisters; Raphael E Pollock; Dina Lev
Journal:  Clin Cancer Res       Date:  2007-12-15       Impact factor: 12.531

4.  Molecular genetic, cytogenetic, and immunohistochemical characterization of alveolar soft-part sarcoma. Implications for cell of origin.

Authors:  C Cullinane; P S Thorner; M L Greenberg; Y Kwan; M Kumar; J Squire
Journal:  Cancer       Date:  1992-11-15       Impact factor: 6.860

5.  Alveolar soft part sarcoma of tongue base - A rare presentation of a rare tumor.

Authors:  S Raghunandhan; Sathiya Murali; Jawahar Nagasundaram; S Sudha Maheswari; Mohan Kameswaran
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2007-12-11

6.  Rare tumor of the tongue in a child: alveolar soft part sarcoma.

Authors:  Alicia Rodríguez-Velasco; Floribel Fermán-Cano; Fernando Cerecedo-Díaz
Journal:  Pediatr Dev Pathol       Date:  2008-07-16
  6 in total
  1 in total

1.  CHARACTERIZATION OF ALVEOLAR SOFT PART SARCOMA OF THE TONGUE: A CLINICO-PATHOLOGIC STUDY AND SCOPING REVIEW.

Authors:  A O Akinyamoju; O O Gbolahan; B F Adeyemi
Journal:  Ann Ib Postgrad Med       Date:  2020-12
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.